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Abstract
Background: Friedreich’s ataxia (FA), the most frequent form of inherited ataxias in the Caucasian population, is caused by a
reduced expression of frataxin, a highly conserved protein. Model organisms have contributed greatly in the efforts to
decipher the function of frataxin; however, the precise function of this protein remains elusive. Overexpression studies are a
useful approach to investigate the mechanistic actions of frataxin; however, the existing literature reports contradictory
results. To further investigate the effect of frataxin overexpression, we analyzed the consequences of overexpressing human
(FXN) and fly (FH) frataxins in Drosophila.
Methodology/Principal Findings: We obtained transgenic flies that overexpressed human or fly frataxins in a general
pattern and in different tissues using the UAS-GAL4 system. For both frataxins, we observed deleterious effects at the
biochemical, histological and behavioral levels. Oxidative stress is a relevant factor in the frataxin overexpression
phenotypes. Systemic frataxin overexpression reduces Drosophila viability and impairs the normal embryonic development
of muscle and the peripheral nervous system. A reduction in the level of aconitase activity and a decrease in the level of
NDUF3 were also observed in the transgenic flies that overexpressed frataxin. Frataxin overexpression in the nervous system
reduces life span, impairs locomotor ability and causes brain degeneration. Frataxin aggregation and a misfolding of this
protein have been shown not to be the mechanism that is responsible for the phenotypes that have been observed.
Nevertheless, the expression of human frataxin rescues the aconitase activity in the fh knockdown mutant.
Conclusion/Significance: Our results provide in vivo evidence of a functional equivalence for human and fly frataxins and
indicate that the control of frataxin expression is important for treatments that aim to increase frataxin levels.
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Introduction
Friedreich’s ataxia (FA), an autosomal recessive disease, is the
most frequent form of inherited ataxias in the Caucasian population
(1:50000) [1]. The major cause of this disease is the presence of a
large GAA repeat expansion in the first intron of the FXN gene [2].
This large GAA repeat decreases the level of transcription of the
mRNA that encodes the protein frataxin [3,4], resulting in levels
that range from 5% to 30% of the normal level of this protein [5].
The clinical manifestations of FA involve spinal cord and
cerebellum neurodegeneration, which cause gait and limb ataxia,
muscular weakness and speech impairments [6,7]. Other manifes-
tations of FA include scoliosis, diabetes and hypertrophic cardio-
myopathy, which is the main cause of death [8].
Frataxin is a highly conserved protein throughout evolution
[9]. This degree of conservation has enabled the development of
FA models in many organisms, from E.coli to the mouse, that
have contributed to a better understanding of this protein’s
function; however, the exact function of frataxin remains elusive.
Seminal findings by a number of key studies have suggested
potential roles for frataxin in iron homeostasis [10–14], as an
activator of the respiratory chain [15–17], as a regulator of Fe-S
cluster assembly through activation [12,18–23] or inhibition [24]
and/or by promoting cellular defense against reactive oxygen
species [25–32].
In Drosophila, the frataxin homolog (fh) shares a high degree of
sequence conservation and projected folding with other frataxin
orthologs [33]. Moreover, a reduction in the level of frataxin
expression in Drosophila has been established as an effective model
to study frataxin function and the pathological mechanisms that
underlie frataxin deficiency. In fact, the loss of fh recapitulates
important behavioral and biochemical features of human disease
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the crucial involvement of oxidative stress, particularly peroxides,
in the development of FA [31,32,35]. These models have also
indicated that frataxin is relevant in glial cells and that these cells
play a role in FA [35]. In addition, these models have revealed that
mitochondrial depolarization is an initial element in the axonal
transport defects that lead to a concomitant dying-back neurop-
athy [36]. Overexpression studies in the fruit fly have been greatly
used to study the gene’s function and to provide insight into the
human inherited pathologies. Among these studies, several reports
of investigations of the ectopic expression of human genes in
Drosophila have provided highly valuable information regarding
Alzheimer’s disease [37], polyglutamine diseases [38], Parkinson’s
disease [39,40] and dominant spinocerebellar ataxias (SCAs)
[41,42].
For frataxin overexpression, the existing literature presents
contradictory results. Experiments in mice [17,43] or in cultured
cells [15,44,45] have revealed that frataxin overexpression was
innocuous or had a positive effect on the cell’s biology, stimulating
the production of ATP or inducing the recruitment of antioxidant
defenses. Similarly, Runko et al. [46] reported that the overex-
pression of Drosophila frataxin promoted cellular resistance to
oxidative stress. However, we have previously reported that
Drosophila frataxin overexpression [31] leads to detrimental
phenotypes in the fly, including developmental defects, a decrease
in the level of aconitase activity and hypersensitivity to oxidative
stress. Notably, the overexpression of frataxin in yeast has also
been shown to critically affect aconitase activity [47].
In the present study, we analyzed the effects of the
overexpression of two frataxins in a multicellular organism,
Drosophila melanogaster. To achieve this aim, we generated
transgenic flies that overexpressed human (FXN) and fly (fh)
frataxins through the UAS/GAL4 system. We also studied
whether FXN can functionally replace endogenous Drosophila
frataxin. In the present paper, we report that the increased
expression of human or fly frataxin in Drosophila leads to
deleterious effects at biochemical, histological and behavioral
levels. We also show that FXN can rescue the reduction in the
aconitase activity that is associated with the loss of frataxin in the
fly. Our results provide in vivo evidence of a functional equivalence
between human and fly frataxins and indicate that the regulation
of frataxin expression is a key factor that underlies frataxin
function.
Materials and Methods
Drosophila stocks
The w
1118 strain of Drosophila was used as the control line and for
the injection of the UAS-FXN construct. The UAS-fh line, which
carried the fh coding sequence under the control of UAS, was
previously generated in our laboratory [31]. The UAS-fh line
induced a 9-fold increase in the level of fh-mRNA at 29uC. The
UD1R2 line was kindly provided by J.P. Phillips (University of
Guelp, Guelp, ON). UD1R2 induced a strong interference of fh,
and the FH protein was reduced to undetectable levels [34]. The
MitoCat flies were a gift from W. Orr (Southern Methodist
University, Dallas, USA). The actin-GAL4, da
G32-GAL4, 24B-
GAL4, neur-GAL4, repo-GAL4 and Appl-GAL4 driver lines were
obtained from the Bloomington Stock Center. The stocks were
maintained at 25uC using standard cornmeal agar medium. The
crosses between the GAL4 drivers and the UAS responder lines
were conducted at either 25uCo r2 9 uC. The rescue experiments
were conducted by generating the following stocks: mitoCat / CyO;
UAS-FXN / TM3; and UDIR2 / CyO; UAS-FXN / TM3.
Construction of the UAS-FXN transgene and the
generation of the fly transformants
The cDNA for FXN was obtained from human fetal brain poli-
(A)+ mRNA (Invitrogen). A 645 bp fragment, which included the
entire coding region of the gene, was amplified using the following
primers: FXN-pUASTf (CTCGAGATGTGGACTCTCGGGC-
GCCG) and FXN-pUASTr (GGTACCTCAAGCATCTTTT-
CCGGAATAGGCCAAG). This fragment was inserted into the
pCR2.1-TOPO vector and was then subcloned into the pUAST
vector to generate the UAS-FXN transgene.
The transgenic flies were generated using standard embryo
injection protocols [48]. Seven independent lines were obtained,
and the presence of the transgene was verified in each line using
PCR with vector-specific primers. The sequencing of the PCR
products revealed that there were no mutations present in the FXN
sequence. The lines were examined for the expression of FXN by
crossing each of these lines with the actin-GAL4 driver line. A line
that contained the UAS-FXN transgene on the second chromo-
some was selected to perform our experiments.
Western blotting
The total protein extraction from the Drosophila larvae was
performed as previously described [49]. The protein levels were
determined using the Bradford assay. The samples were separated
on 5% stacking, 15% separating SDS polyacrylamide gels. The
resolved proteins were electroblotted to a Hybond-ECL nitrocel-
lulose membrane (GE Healthcare) and were probed using mouse
anti-FXN (Chemicon, Millipore, 1:2000), mouse anti-NDUFS3
(Mitosciences MS112, 1:2000) or mouse anti-a-tubulin (Sigma-
Aldrich, 1:2500) antibodies. Fluorescent goat anti-mouse was used
as the secondary antibody in these cases. Detection and
quantification was conducted using the Odyssey system (Li-cor
Inc.). Alternatively, goat anti-mouse IgG horseradish peroxidase
conjugate (Sigma-Aldrich) was used as a secondary antibody and
was detected using ECL Detection Reagent (GE Healthcare).
Immunohistochemistry staining
The whole mount embryo staining technique with horseradish
peroxidase was conducted as previously described [50]. The
embryos were incubated with the following primary antibodies:
mouse mAb anti-myosin heavy chain (anti-MHC), 1:8 dilution, a
gift from D. Kiehart; mouse mAb 22C10 anti-peripheral nervous
system neurons (anti-PNS), 1:50 dilution; mouse mAb BP102 anti-
central nervous system axons (anti-CNS), 1:200 dilution, from the
Developmental Studies Hybridoma Bank; and rabbit anti-even-
skipped protein, 1:2000 dilution, kindly provided by M. Frasch.
The Ab-antigen complexes were detected using biotinylated horse
anti-mouse IgG (Pierce, Rockford, IL) or biotinylated goat anti-
rabbit IgG (Pierce) antibodies.
Brain histology
For the examination of the adult fly brains using light and
electron microscopy, ultrathin Epon plastic sections were post-
stained with 2% uranyl acetate, which was followed by Reynolds’
lead citrate. Next, the sections were stabilized for transmission
electron microscopy using carbon coating. The examination was
conducted using a Zeiss EM10C/VR electron microscope at
80 kV. The glial cell material was identified by its characteristi-
cally higher electron density.
Life span determination and climbing assay
For the life span determination, the male flies were collected
within 24 h of eclosion and were raised at 25uC under a 12 h:12 h
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every 2–3 days. The climbing assay was conducted as described in
Botella et al. [51].
Assay of the aconitase activity
The total aconitase activity was determined from L3 larvae
using the Bioxytech Aconitase-340
TM Spectrophotometric Assay
Kit (Oxis International Inc, Portland, OR).
Hyperoxia treatment
The hyperoxia treatment was started one day post-eclosion and
was performed as previously described [31]. To measure the
aconitase activity, L3 larvae were maintained in hyperoxia
conditions for a 24 h period before performing the assay.
Gel filtration chromatography
The mitochondria from the actin-GAL4.UAS-FXN larvae were
isolated (MITOISO1, Sigma), lysed in hypotonic buffer (HEPES
10 mM, pH 7.0) and sonicated (three times for 30 sec) before
being centrifuged at 20,000 g for 30 min. The mitochondrial
matrix proteins were subjected to size exclusion chromatography
on a Superdex 200 10/300 GL column with a fractionation range
of 10 to 600 kDa (GE Healthcare) and were eluted with 50 mM
HEPES and 140 mM NaCl, pH 8.0, at a flow rate of 0.5 ml/min.
Blue Dextran 2000 (1 mg/ml) was used to estimate the void
volumes, and gel filtration molecular weight standards (GE
Healthcare) were used to calibrate the column. An equal volume
of each fraction was analyzed using SDS-PAGE and western
blotting.
Statistical analysis
A Kaplan-Meier analysis of the survival data with a semi-
parametric log rank test was performed using Graph Pad Prism
4.0 software. The differences in the locomotor and aconitase
activities were tested using a one-way ANOVA test, using the
Statistical Packages for the Social Sciences (SPSS) v17.0. A value
of p,0.05 was considered to be statistically significant.
Results
Human frataxin is correctly expressed and targeted to
the mitochondria in Drosophila
To investigate the effect of human FXN expression in D.
melanogaster, we generated transgenic flies that carried the UAS-
FXN construct. These flies were crossed with the da-GAL4 driver
line at 25uC to reach the ubiquitous expression of the human gene.
Because the da-GAL4.UAS-FXN individuals exhibited lethality
beforeadulteclosion,the presenceofhumanfrataxinwasconfirmed
in the transgenic larvae using western blotting. As expected, human
frataxin was only detected in the da-GAL4.UAS-FXN larvae; no
signalwasobservedinthedriverandrespondercontrols(Figure1A).
To test whether FXN was transported into the mitochondria, we
analyzed the relative amount of frataxin in the mitochondrial and
cytosolic fractions. We used an anti-actin antibody as a control for
cytosolic contamination. In three independent experiments, the
amount of frataxin was consistently found to be 8-10 times higher in
the mitochondrial fraction in comparison to the cytosolic fraction,
with only a residual amount of frataxin being present in the
cytoplasm. The quantity of actin was similar in both fractions.
Therefore, our results indicate that human frataxin is mainly
localized withinthemitochondria inDrosophila cells, asitexhibits the
same subcellular localization as endogenous Drosophila frataxin [31].
Human frataxin overexpression reduces Drosophila
viability
We have previously reported the consequences of increasing
the amount of fh expression in Drosophila [31]. We found that
the general and mesodermal overexpression of fh at 29uC
resulted in lethality during the pre-adult stages and restricted
the expression of fh in the nervous system, which had no effect
on viability.
To test whether the effect of FXN overexpression on Drosophila
viability was similar to the effect of the overexpression of fh, we first
investigated systemic FXN expression with the ubiquitous da-GAL4
and actin-GAL4 drivers by mating the flies at 25uC and 29uC. Full
lethality was observed with both drivers at both temperatures.
These results were similar to those after the fh overexpression
(Table 1); however, deaths were observed earlier in the individuals
with FXN expression than in those with fh overexpression.
Next, we examined the consequences of a tissue-specific
expression of FXN. The FXN expression was specifically driven
Figure 1. Effect of FXN overexpression in the embryonic
development. (A) Detection of the FXN protein in da-GAL4.UAS-
FXN (+,+) larvae in the mitochondrial (mito) and the cytosolic (cyto)
fractions. The control genotypes of the larvae were da-GAL4.yw (+,2)
and yw.UAS-FXN (2,+). The human frataxin protein was localized in
the mitochondria. Anti-actin was used as a control for cytosolic
contamination. (B–G) Muscular and nervous system defects in da-
GAL4.UAS-FXN and actin-GAL4.UAS-FXN embryos at stage 16. In
these panels, anterior is toward the left, and all of the views are lateral
views. Anti-myosin staining revealed abnormalities in the junctions of
lateral transversal muscles 1, 2 and 3 and the ventral longitudinal
muscle 1 (C) compared with the control (B). Moreover, a few embryos
exhibited abnormalities in the muscular development of mutant (E)
versus control (D) embryos. Staining with 22C10 detected strong
abnormalities in the axonal path finding of the sensory nerves (G) with
respect to the control (F).
doi:10.1371/journal.pone.0021017.g001
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most affected tissues in patients with FA. The FXN expression in
the embryonic mesoderm (24B-GAL4) led to the death of all of the
individuals that were early to late pupae. However, we observed
viable progeny that expressed FXN in the central nervous system
(CNS), in the sensory organs and their precursors and in the glial
cells, using the Appl-GAL4, neur-GAL4 and repo-GAL4 drivers,
respectively. In contrast, the expression of FXN at 29uC with the
neuronal post-mitotic driver Appl-GAL4 resulted in pre-adult
lethality (Table 1).
Collectively, these results demonstrate that tissues respond
similarly to Drosophila and human frataxin overexpression and that
an adequate balance of the systemic synthesis of frataxin is critical
for fly viability.
The general expression of FXN disrupts normal
Drosophila development
Inmunohistochemical staining was conducted in da-GA-
L4.UAS-FXN and actin-GAL4.UAS-FXN embryos to identify
the underlying defects that were associated with the lethal
phenotypes. Anti-myosin staining of the muscular system
revealed defects in the junctions of lateral transversal muscles
1, 2 and 3 with ventral longitudinal muscle 1, which was likely
due to deficient muscle growth (Figure 1C). Defects in several
muscles were also reported after fh overexpression [31]. In a few
cases, we observed FXN-expressing embryos that exhibited a
disrupted muscular system (Figure1 E ) .A f t e rt h ee m b r y o ’ sP N S s
were stained using the 22C10 antibody, a strong disorganization
of the sensory axons was detected (Figure 1G). Similar
alterations were described for the da-GAL4 driven overexpres-
sion of fh [31]. No abnormalities were found in the CNS of the
FXN-expressing embryos when they were stained using the
BP102 antibody (as in da-GAL4.UAS-fh embryos; data not
shown).
We observed that the lethal phenotypes that were associated
with the general overexpression of human or fly frataxin mainly
resulted from the impairment of correct muscle and PNS
development, whereas the CNS was not affected. The high degree
of similarity between the defects that were observed with the
overexpression of human and fly frataxins supports the involve-
ment of the overexpression of FXN in the same developmental
mechanisms than FH overexpression. In addition, these results
indicate that the frataxin level is critical for the normal embryonic
development of muscle and the PNS.
Nervous system expression of FXN shortens life span,
impairs locomotor performance and causes brain
degeneration
We further assessed whether human frataxin expression in
neural tissues affects Drosophila fitness during adulthood. The
length of the life span was examined using the Appl -GAL4, neur -
GAL4 and repo-GAL4 drivers. The FXN flies exhibited a
statistically significant decline in the mean (75%, 80% and 50%,
respectively) and maximum life spans (74%, 75% and 56%,
respectively). These decreases were larger than those that were
observed after the overexpression of endogenous fly frataxin
(Figure 2A–C).
To study the effect of frataxin overexpression on the nervous
system functioning in Drosophila, the locomotor activity of the flies
was analyzed. The overexpression of human or fly frataxin
reduced the climbing ability of the flies in an age-dependent
manner for all three of the drivers used. The larger reduction was
observed for FXN with neur-GAL4 driver, which exhibited a 70%
reduction in the 5-day-old flies and a 90% reduction in the 10-day-
old flies (Figure 2E). Appl (Figure 2D) and repo-GAL4 (Figure 2F)
also induced locomotor dysfunctions, although to a lesser extent
(55% and 25% in 5-day-old flies, respectively). The findings
indicate that aging appears to exacerbate the reduction in
locomotor ability that results from frataxin overexpression.
To identify the cellular pathology underlying the life span and
locomotor phenotypes that have been associated with frataxin
overexpression, the brain sections from flies that overexpressed
human frataxin were analyzed using light and electron microsco-
py. The selective FXN expression in glial cells induced a strong
age-related degeneration in the cortex and a neuropil vacuoliza-
tion with the presence of droplet-like structures (Figure 3D). An
ultrastructural analysis revealed a complete morphological disrup-
tion of the glial cells and the concomitant formation of lipid
droplets (Figure 3E). Notably, a very similar phenotype was
observed in the glial cells that lacked Drosophila frataxin [35].
Moreover, as shown in Figure 3F, several regions of the brain
exhibited clear mitochondrial phenotypes, such as an abnormal
morphology or vacuolization. Although the Appl-GAL4 . UAS-
FXN flies exhibited a clear locomotor deficit and a shortened life
span, these flies did not display brain abnormalities compared to
the control age-matched individuals (data not shown).
These results indicate that an excess of frataxin impairs
embryonic development and negatively affects fly fitness. Remark-
ably, our results from glial cells may suggest that frataxin
overexpression alters cellular homeostasis in a similar manner to
frataxin knock-down. These data indicate that a balance of
frataxin levels is critical for the correct functioning of several cell
types in the Drosophila nervous system.
Overexpression of human frataxin enhances
susceptibility to oxidative stress
One of the most characteristic biochemical defects that is
associated with a loss of frataxin is the reduction of aconitase
activity [18,19,31]. Therefore, we tested whether the overexpres-
sion of human frataxin in Drosophila would also affect the activity of
this enzyme. Aconitase activity was measured in actin-GA-
L4.UAS-FXN L3 larvae because the ubiquitous expression of
FXN caused lethality before adult eclosion (Table 1). Notably,
these larvae exhibited a 50% reduction in aconitase activity under
normoxia conditions (Figure 4A).
Several FA models have also resulted in a strong reduction of
other Fe-S-cluster-containing proteins, such as the complex I
subunit, SdhA, SdhB or the Rieske protein [52,53]. Thus, we
Table 1. The effect of general and tissue-specific expression
of human and fly frataxins on Drosophila viability at 25uC and
29uC.
Expression
pattern
GAL4
drivers
FXN
expression
fh
overexpression
Ubiquitous actin Lethal Lethal
da Lethal Lethal
Muscular system 24B Lethal Lethal
Nervous system Appl Viable at 25uC Viable
Lethal at 29uC
neur Viable Viable
repo Viable Viable
doi:10.1371/journal.pone.0021017.t001
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similar effect on the NDUFS3 levels. In agreement with the
results of other studies [52,53], we observed that FXN overex-
pression triggered a 40% reduction in the amount of NDUFS3
protein expression (Figure 4B) without a change in the mRNA
levels (data not shown), which excludes the possibility of a
transcriptional regulatory mechanism. The reduction of the
aconitase activity and the decrease in the amount of NDUFS3
expression are direct evidence of a reduction in the Fe-S cluster
formation in our overexpression model.
Given that aconitase is a specific target of oxidative stress
[54,55], we assessed the functional integrity of aconitase in FXN
larvae after oxidative stress injury. As expected, the ubiquitous
expression of FXN, combined with a hyperoxia treatment, also
resulted in a two-fold reduction in aconitase activity compared to
hyperoxia-treated controls (Figure 4A). Moreover, aconitase was
seriously affected in flies with general fh overexpression that was
combined with hyperoxia [31].
To test whether oxidative stress was involved in the phenotypes
that were observed in the nervous system, we exposed flies that
overexpressed FXN to a highly oxidative atmosphere (99.5% O2).
Under these conditions, we observed a strong decrease in the
mean (65%) and maximum life span (50%) when compared to
those of the controls (Figure 4C–E). Again, the FXN flies displayed
stronger phenotypes than the flies that overexpressed fh.
In Drosophila, a constitutive increase in the mitochondrial-driven
catalase (mitoCat) activity is known to improve the resistance to
oxidative damage [56]. Moreover, the expression of this enzyme
has been reported to extend the life span of frataxin-deficient flies
and to improve the resistance of these flies to oxidative insult [32].
Therefore, we examined the effect of this free radical scavenger on
life span and locomotor performance in our frataxin overexpress-
ing flies. As illustrated in Figure 4F, mitoCat produced a significant
prolongation of life span when frataxin was overexpressed using
neur-GAL4 and caused a statistically non-significant increase for
repo-GAL4 (Figure 4G). In addition, mitoCat ameliorated the
climbing deficiency that was induced by FXN or fh overexpression
in glial cells (Figure 4H).
These results clearly identify oxidative stress and mainly
hydrogen peroxides as key factors in the frataxin overexpression
phenotypes that have been observed.
Overexpressed FXN do not form aggregates or misfold in
Drosophila
The overexpression of human or Drosophila frataxins produce a
phenotype that is surprisingly similar to the phenotype that is
observed in frataxin-depleted mutants. Thus, we assessed whether
the overexpression of frataxin would induce neomorph phenotypes
and lead to a loss of function phenocopy via protein aggregation or
misfolding.
Heat shock proteins have been reported to display rescuing
effects in Drosophila neurodegenerative models of protein misfold-
ing or aggregation [57–59]. Therefore, we assessed whether the
co-expression of heat-shock proteins would lead to beneficial
effects in our frataxin overload scenarios. Human heat-shock
cognates were used in combination with FXN, and Drosophila
Hsp70 and Hsp22 were co-expressed with fh; however, these heat-
shock proteins were not able to improve the climbing performance
of the frataxin-overexpressing flies (data not shown).
Size exclusion chromatography was conducted for the mito-
chondrial matrix proteins from the FXN-overexpressing larvae,
and the fractions that were obtained were analyzed using western
blotting for the presence of FXN. In our experiments, after the
overexpression of FXN in Drosophila, human frataxin was recovered
Figure 2. Physiological and behavioral defects induced by frataxin overexpression in nervous system. (A–C) Life span under normoxia
conditions. Overexpression of human (black square) or Drosophila (black circle) frataxin in a pan-neural fashion (A), in the sensory organs and their
precursors (B) or the glial cells (C) dramatically shortens the mean and maximum life span compared to control flies (white square). (D–F) Negative
geotaxis experiment with 5- and 10-day-old individuals. Overexpression of frataxin in all 3 nervous system cell types strongly reduced the walking
ability of the flies. The strongest effect was observed when the PNS driver (neur-GAL4) was applied. The statistical differences between the survival
curves in A, B and C were analyzed using the Kapplan-Meier test, and both of the frataxins exhibited a statistically significant reduction (p,0.001)
compared to that of the control individuals. The level of significance in D, E and F was determined using a one-way ANOVA with the post hoc
Newman-Keuls test (* p,0.05). The error bars represent the standard error.
doi:10.1371/journal.pone.0021017.g002
Overexpression of Human Frataxin in Drosophila
PLoS ONE | www.plosone.org 5 July 2011 | Volume 6 | Issue 7 | e21017as a monomeric form (Figure 5A), and no high molecular weight
frataxin aggregates (dimers, trimers or multimeric forms of
frataxin) were detected in the void volume (fraction 14). It was
nevertheless possible that frataxin protein aggregates were not
solubilized with the mitochondrial matrix proteins. Insoluble
cellular proteins were solubilized, and the western blot did not
reveal the presence of frataxin in this solubilized fraction (data not
shown).
Collectively, these results indicate that frataxin aggregation or
misfolding is unlikely to be the mechanism behind the phenotypes
that have been observed.
FXN overexpression restores the aconitase activity in fh
deficient individuals
In terms of their sequences and other structural properties, the
degree of conservation between FH and FXN [33,60] indicates a
possible similarity in the function of these proteins. In support of
this hypothesis, we have shown that Drosophila and human frataxin
overexpression produce similar phenotypes. Lastly, we investigated
the consequences of expressing FXN in fh-knockdown flies. To
accomplish this task, we generated flies by combining FXN and
UDIR2 transgenes, and the latter transgene induced a 90%
reduction in the level of fh expression [34].
A decrease in the level of aconitase activity appears to be the
most sensitive biological and biochemical marker in the FA fly
models [31–35]. As a result, we tested whether aconitase could be
rescued in fh knockdown flies expressing FXN. In agreement with
previously published results [34], the depletion of fly frataxin led to
a two-fold reduction in aconitase activity in larvae compared to
controls. Remarkably, the expression of FXN prevented aconitase
inactivation, and the aconitase activity was recovered to levels that
were comparable with those of the controls (Figure 4A).
Considering the possibility that the rescue of the aconitase
activity was related to degradation of the FXN mRNA that was
induced by the RNAi transgene directed to fh, we assessed the
human frataxin protein levels using western blotting. Comparable
levels of FXN were observed in the actin-GAL4.UAS-FXN and
actin-GAL4.UAS-UDIR2;UAS-FXN larvae (Figure 4B).
We can conclude that human frataxin is able to replace the
endogenous Drosophila frataxin, which suggests that these proteins
play an equivalent role in the cell biology of these organisms.
Discussion
Friedreich’s ataxia is the most common autosomal recessive
ataxia in the Caucasian population. This disease exhibits an
irreversible progression that confines a patient to a wheelchair and
leads to an early death. Moreover, although different treatments
are currently being developed and assessed in clinical trials, there
is no cure available. To generate effective and adequate therapies
for Friedreich’s ataxia, it is imperative to define the function of the
frataxin protein. Unfortunately, the precise function of this protein
is still a matter of debate. Although overexpression studies do not
represent a disease model for FA, these studies are a useful
approach to decipher the mechanism of action of frataxin.
Figure 3. Strong degeneration and lipid droplet accumulation in glial cells overexpressing frataxin. (A–C) 25-day-old Repo-GAL4 / +
controls; (D–F) 25-day-old Repo-GAL4 / UAS-FXN. (D) Overexpression of human frataxin induced a strong degeneration in the cortex (white arrow and
3X magnification box). (E, F) The electron microscopy analysis revealed an accumulation of lipid droplets (denoted by asterisks; E) in the glial cellso f
the frataxin-overexpressing brains and revealed mitochondria with altered morphologies (arrows; F) and internal vacuolization (arrow heads; F). The
scale bar represents 50 mm (A, D) and 2.5 mm (B, C, E, F).
doi:10.1371/journal.pone.0021017.g003
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an excess of frataxin, which is a critical factor for the validation of
treatments that are based on an increase in this protein’s
expression.
Frataxins are a highly conserved family of proteins. In silico
analyses have shown that Drosophila frataxin and frataxin proteins
that are found in other species share large percentages of identity
and similarity in their sequence and a common secondary
structure [33]. The closest match between the human and the
fly frataxins involves a stretch of 38 amino acids at the C-terminus,
which is encoded by fh exon 2, and exons 4 and 5a of the FXN
gene, respectively. This highly conserved region is very likely to
form a functional domain with a b-sheet structure that is flanked
by a-helices, where the sequence is less conserved [33]. Moreover,
Drosophila frataxin has similar biophysical properties to human
frataxin [60] and exhibits a mitochondrial localization [31]. In
agreement with mouse models of FA [19], a strong systemic
depletion of fh induces lethality during early development [31,34],
whereas the moderate reduction of fh produces phenotypes that
parallel the symptoms of FA patients [31]. In addition, the tissue-
specific silencing of frataxin leads to the mimicking of human
phenotypes [31,34–36]. Collectively, these data indicate that these
proteins may be playing identical roles; however, their functional
equivalence had not yet been demonstrated experimentally.
In the present work, we generated a Drosophila strain that
overexpressed the human frataxin (FXN). Flies with an increased
Figure 4. Molecular effects of frataxin overexpression and the involvement of oxidative stress. (A) The negative effects of human-
frataxin overexpression on aconitase activity under normoxia and hyperoxia (99.5% O2) conditions. (B) Human frataxin overexpression triggered a
reduction in the synthesis of the complex I subunit (amount normalized to the internal control a-tubulin). (C–E) Increased susceptibility to hyperoxia-
mediated oxidative damage in flies overexpressing human and fly frataxin in the nervous system. (F,G) Constitutive expression of mitochondrial
catalase (mitoCat) led to an extension of the mean and maximum life span of the flies with increased frataxin expression. This effect was strong in the
peripheral nervous system (neur-GAL4) and moderate in the glial cells (repo-GAL4). (H) Co-expression of mitochondrial catalase (mitoCat) rescues (5d)
and alleviates (10d) the locomotor deficits in the flies with an increased level of frataxin expression in the glial cells. The survival curves were analyzed
using the Kapplan-Meier test. The level of significance in A, B and H was determined using a one-way ANOVA with a post hoc Newman-Keuls test
(*p,0.05). The error bars represent the standard error.
doi:10.1371/journal.pone.0021017.g004
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after endogenous frataxin overexpression, such as an alteration of
development, a reduction in viability, life span and motor ability
[31] and clear manifestations of nervous system degeneration,
impaired Fe-S cluster formation and an enhanced susceptibility to
oxidative stress. These results support the hypothesis that these
frataxins are functionally equivalent. In the present work, we have
shown that FXN was able to recover aconitase activity, the most
sensitive biochemical marker of FA, in frataxin-deficient larvae.
Although the effect of frataxin overproduction has been
investigated in several models, our studies using Drosophila as a
model are the only studies to show deleterious defects. Human
frataxin overexpression has been reported to be innocuous in mice
[43] or to stimulate energy production [17]. Frataxin promotes
OXPHOS activation in cell culture [15,45] and increases cellular
antioxidant defense in cell culture and yeast [44,47]. In agreement
with these findings, the overexpression of frataxin in Drosophila that
was conducted by Runko et al. [46] increased the resistance to
oxidative stress and extended the life span of the flies. These
differences may be related to the characteristics of the models but
may also result from quantitative differences in the level of frataxin
overproduction. A closer look at the data from these studies reveals
that a slight overexpression of frataxin was reported, from 2 to 6
times that of baseline, depending on the model and/or the tissue
that was used. Conversely, in the present work, and in Llorens et al.
[31], a minimum of 9-fold increase in frataxin production was
induced. Therefore, it is possible that moderate overproduction of
this protein may lead to beneficial effects, whereas the expression
of frataxin beyond a given threshold may have multiple effects
inducing toxicity. Taken together, these results indicate that
frataxin requires an optimal balance of its expression level to carry
out its function properly. To date, very little is known about the
regulation of frataxin expression. It has been reported that the
transcription factors Hypoxia-inducible Factor 2alpha [61], SRF and
TFAP2 [62] are involved in regulating the expression of frataxin,
as may be the iron content of the cell [63]. Analyzing the
mechanism of this regulatory network is a new field that will
provide new targets for future therapies.
In agreement with the results of the present study, the
overproduction of yeast frataxin has been shown to impair Fe-S
cluster formation and to lead to a reduction in aconitase and SDH
activities [47]. These authors proposed that the trimeric form of
frataxin may be responsible for the interaction with the complex of
iron-sulfur cluster machinery. Thus, the increase in frataxin
oligomerization due to its overexpression would lower the amounts
of trimers that restrict the production of the cluster. To clarify the
toxic mechanism that is responsible for frataxin overexpression in
Drosophila, we considered the possibility that FXN was also
inducing protein aggregation or misfolding, leading to a reduction
in the level of functional frataxin. However, the results of our gel
filtration assays did not show any shift in FXN to higher molecular
masses, and the protein was recovered in the monomeric form. In
addition, the overexpression of human or fly heat-shock proteins
did not lead to any improvement in the frataxin overexpression
phenotypes. These results indicate that protein aggregation and
misfolding are not the central factors leading to the frataxin
overexpression defects. Notably, our results do not reproduce the
data from the experiments using bacterial [64,65] or yeast [47,66]
models in which frataxin forms multimers. These findings indicate
that oligomerization does not occur in Drosophila. Our results are in
agreement with the findings of Kondapalli et al. [60], who reported
that FH seems to be less prone to aggregation in vitro than the yeast
protein, which appeared as a monomer in most of the conditions
that were tested.
In our overexpression model, we observed aconitase inactiva-
tion and a reduction in the NDUFS3 levels, indicating an
alteration in Fe-S cluster formation. These results argue in favor of
the role of frataxin as an inhibitor of the Fe-S cluster assembly
machinery, as previously suggested by Adinolfi et al. [24].
However, this inhibitory function is not consistent with the
Figure 5. FXN does not form aggregates in Drosophila, and its expression is not diluted when it is coexpressed with the interference
of fh. (A) Mitochondrial cell extracts were obtained from actin-GAL4.UAS-FXN larvae and were size fractionated. The fractions were subsequently
analyzed using SDS-PAGE and western blotting with an anti-human frataxin antibody. The positions of ferritin (440 kDa), aldolase (158 kDa),
conalbumin (75 kDa), and ovalbumin (44 kDa) and the estimated position for the frataxin monomer and dimer are indicated as arrowheads and
arrows, respectively. (B) Detection of FXN protein in actin-GAL4.UAS-FXN and actin-GAL4.UDIR2; UAS-FXN larvae. The FXN protein is not diluted
when it is co-expressed with an RNA interference construct of fh. a-tubulin was used as a loading control.
doi:10.1371/journal.pone.0021017.g005
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other authors [15,17,45]. Therefore, we propose that a moderate
overexpression of frataxin may promote the synthesis of clusters or
promote their stabilization when they are incorporated into apo-
proteins, as has been previously suggested [16,28]. In contrast, a
larger increase in the overexpression of frataxin may lead to a
reduction in Fe-S cluster formation, regardless of this proteins
function as an activator [12,18–23] or suppressor [24], by
saturating the ISC machinery or by sequestering the proteins
from the machinery that interact with frataxin. Frataxin has been
recently proposed to maintain the ISCU/NFS1/ISD11 interac-
tion [23]; however, an increase of frataxin may over-stabilize this
complex and cause an Fe-S cluster deficiency.
Our results that show the constitutive expression of mitochon-
drial catalase demonstrate that oxidative stress and hydrogen
peroxides are key factors in the frataxin overexpression pheno-
types. Notably, the positive effect of mitochondrial catalase in
counteracting frataxin defects has been previously reported [32].
These results suggest a common mechanism in the loss-of-function
and gain-of-function phenotypes that are induced by frataxin.
Remarkably, in Llorens et al. [31] and in the present study, other
similar phenotypes between strong frataxin overproduction and
frataxin depletion have been described, such as structural defects
that lead to a reduction in longevity and locomotor capabilities
and an increased sensitivity to oxidative damage. Moreover, the
overexpression of FXN in glial cells leads to the presence of the
lipid droplets and the brain degeneration that have been exhibited
by glial-frataxin deficient flies [35].
In conclusion, we demonstrate that overexpression of Drosophila
and human frataxins induces severe developmental problems in
flies, a shortening of life span, brain degeneration and reduced
aconitase activity. Moreover, the control of frataxin expression
emerges as a crucial element for present and future treatments,
such as gene therapy approaches, aimed at increasing frataxin
levels.
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